Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

Author:

Djebbari FaouziORCID,Sharpley Faye A.,McLain-Smith Susan,Vallance GrantORCID,Eyre Toby A.,Kothari Jaimal,Moore Sally,Ramasamy Karthik

Funder

Celgene

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference16 articles.

1. Cancer Research UK. Cancer statistics: Myeloma incidence statistics. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence. Accessed April 4, 2018

2. Management of multiple myeloma in the newly diagnosed patient;American Society of Hematology;Hematology,2017

3. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma;FIRST Trial Team;New England Journal of Medicine,2014

4. Continuous lenalidomide treatment for newly diagnosed multiple myeloma;MM-015 Investigators;New England Journal of Medicine,2012

5. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma;Alcyone Trial Investigators;New England Journal of Medicine,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3